Edding Genor Doses First Patient in Phase Ib/II Trial of Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Metastatic Breast Cancer
核心洞察
Edding Genor has dosed the first subject in a Phase Ib/II trial of GB268, a PD-1 (搜索)/CTLA-4 (搜索)/VEGF (搜索) trispecific antibody, in patients with locally advanced unresectable or metastatic breast cancer.
The open-label, multi-cohort study will enroll up to 270 patients and evaluate GB268 as monotherapy, in combination with chemotherapy, and with antibody-drug conjugates across first-line through later-line settings.
Early dose-escalation data show GB268 reached 30 mg/kg without dose-limiting toxicity, with promising anti-tumor activity and a favorable safety profile.
Edding Genor Group Holdings Limited (搜索) (HKEX: 06998) announced on August 6 that the first subject has been dosed in the Phase Ib/II clinical trial of GB268, a PD-1 (搜索)/CTLA-4 (搜索)/VEGF (搜索) trispecific antibody, in patients with locally advanced unresectable or metastatic breast cancer. The milestone marks the entry of GB268 into breast cancer-specific clinical testing, with the company planning to present Phase I monotherapy data at the European Society for Medical Oncology (ESMO) congress in the fourth quarter of 2026.
The trial follows approval from China's National Medical Products Administration (NMPA) for the Investigational New Drug application, positioning GB268 as a cornerstone candidate in Edding Genor's immuno-oncology portfolio.
Mechanism and Rationale
GB268 simultaneously targets PD-1 (搜索), CTLA-4 (搜索), and VEGF (搜索), combining dual immune checkpoint blockade with anti-angiogenic activity in a single molecule. This trispecific approach aims to improve upon conventional PD-1-based immunotherapy by simultaneously addressing immune suppression and tumor angiogenesis. The design aligns with a broader wave of next-generation multispecific checkpoint antibodies, including BeOne Medicines/Huahui Health's HH160, a PD-1/CTLA-4/VEGF-A-targeted trispecific antibody that entered first-in-human testing in June 2026.
Trial Design and Patient Population
The open-label, multi-cohort, multi-center study, registered with China's NMPA under identifier CTR20262740, is designed to enroll up to 270 patients across multiple cohorts. The trial is enrolling patients with triple-negative breast cancer (搜索) (TNBC) and hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer — two subtypes that differ substantially in biology and standard-of-care management but share limited options in later lines.
The study evaluates GB268 as monotherapy, in combination with chemotherapy, and in combination with antibody-drug conjugates (ADCs). Primary endpoints cover safety and tolerability in combination settings — including dose-limiting toxicity (DLT) — and preliminary anti-tumor activity across both monotherapy and combination arms. The protocol is designed to span first-line through later-line settings.
Early Safety Signals
Early dose-escalation data indicate that GB268 has reached 30 mg/kg without dose-limiting toxicity, with promising anti-tumor activity and a favorable safety profile. These findings support the drug's potential in broader oncology use, though no efficacy or safety data from the current breast cancer trial have been reported at this stage.
Competitive Landscape
GB268 will ultimately need to compete against established therapies such as TROP2-directed ADCs, including Trodelvy and Datroway. However, its trispecific immunotherapy approach differentiates it from these agents by targeting both immune checkpoints and angiogenesis in a single molecule.
Strategic Implications
The NMPA approval enables Edding Genor to begin testing GB268-based combination regimens as an immunotherapy backbone and lays groundwork for additional studies in advanced solid tumor indications. For stakeholders, the move signals operational progress in the company's R&D strategy, greater visibility in the global oncology community, and a possible path toward new treatment options for difficult-to-treat breast cancer and other solid tumors, subject to clinical outcomes. The anticipated ESMO 2026 presentation could further validate the asset and influence investor and partner interest in the pipeline.